|
[1]
|
Verma, M., Obergfell, K., Topp, S., Panier, V. and Wu, J. (2023) The Next-Generation CAR-T Therapy Landscape. Nature Reviews Drug Discovery, 22, 776-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Irvine, D.J., Maus, M.V., Mooney, D.J. and Wong, W.W. (2022) The Future of Engineered Immune Cell Therapies. Science, 378, 853-858. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Collins, S.J., Lawson, V.A. and Masters, C.L. (2004) Transmissible Spongiform Encephalopathies. The Lancet, 363, 51-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., et al. (2020) Tumor Microenvironment Complexity and Therapeutic Implications at a Glance. Cell Communication and Signaling, 18, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Shalek, A.K., Satija, R., Shuga, J., Trombetta, J.J., Gennert, D., Lu, D., et al. (2014) Single-Cell RNA-Seq Reveals Dynamic Paracrine Control of Cellular Variation. Nature, 510, 363-369. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Smolders, J., Steelman, A.J. and Inoue, M. (2023) Editorial: Environmental Factors Influencing the Immune Functions during Multiple Sclerosis. Frontiers in Immunology, 14, Article ID: 1141014. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Feng, S., Zhao, X., Zhou, X., Ye, X., Yu, X., Jiang, W., et al. (2021) Epidemiological and Clinical Characteristics of Sporadic Creutzfeldt-Jakob Disease: A Retrospective Study in Eastern China. Frontiers in Neurology, 12, Article ID: 700485. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Orrù, V., Steri, M., Sidore, C., Marongiu, M., Serra, V., Olla, S., et al. (2020) Complex Genetic Signatures in Immune Cells Underlie Autoimmunity and Inform Therapy. Nature Genetics, 52, 1036-1045. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Jones, E., Hummerich, H., Viré, E., Uphill, J., Dimitriadis, A., Speedy, H., et al. (2020) Identification of Novel Risk Loci and Causal Insights for Sporadic Creutzfeldt-Jakob Disease: A Genome-Wide Association Study. The Lancet Neurology, 19, 840-848. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Freuer, D., Meisinger, C. and Linseisen, J. (2021) Causal Relationship between Dietary Macronutrient Composition and Anthropometric Measures: A Bidirectional Two-Sample Mendelian Randomization Analysis. Clinical Nutrition, 40, 4120-4131. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Davies, N.M., Holmes, M.V. and Davey Smith, G. (2018) Reading Mendelian Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians. BMJ, 362, k601. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Pierce, B.L., Ahsan, H. and VanderWeele, T.J. (2010) Power and Instrument Strength Requirements for Mendelian Randomization Studies Using Multiple Genetic Variants. International Journal of Epidemiology, 40, 740-752. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Bowden, J., Davey Smith, G., Haycock, P.C. and Burgess, S. (2016) Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology, 40, 304-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Verbanck, M., Chen, C., Neale, B. and Do, R. (2018) Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian Randomization between Complex Traits and Diseases. Nature Genetics, 50, 693-698. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Burgess, S. and Thompson, S.G. (2017) Interpreting Findings from Mendelian Randomization Using the Mr-Egger Method. European Journal of Epidemiology, 32, 377-389. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Centers for Disease Control and Prevention (CDC). About Prion Diseases|Prions|CDC. https://www.cdc.gov/prions/index.html
|
|
[17]
|
Soto, C. and Satani, N. (2011) The Intricate Mechanisms of Neurodegeneration in Prion Diseases. Trends in Molecular Medicine, 17, 14-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Szpak, G., et al. (2006) The Brain Immune Response in Human Prion Diseases. Microglial Activation and Microglial Disease. I. Sporadic Creutzfeldt-Jakob Disease. Folia Neuropathologica, 44, 202-213. https://pubmed.ncbi.nlm.nih.gov/17039416/
|
|
[19]
|
Xiong, H., Tang, Z., Xu, Y., Shi, Z., Guo, Z., Liu, X., et al. (2022) Cd19+CD24highCD27+ B Cell and Interleukin 35 as Potential Biomarkers of Disease Activity in Systemic Lupus Erythematosus Patients. Advances in Rheumatology, 62, Article No. 48. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Moon, S.Y., Han, M., Ryu, G., Shin, S., Lee, J.H. and Lee, C.S. (2023) Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. International Journal of Molecular Sciences, 24, Article No. 15072. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ishida, Y., Gao, J. and Murphy, P.M. (2008) Chemokine Receptor CX3CR1 Mediates Skin Wound Healing by Promoting Macrophage and Fibroblast Accumulation and Function. The Journal of Immunology, 180, 569-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Probasco, J.C. (2022) First-in-Human Immunotherapy Treatment Trial in Creutzfeldt-Jakob Disease. NEJM Journal Watch. https://www.jwatch.org/na54902/2022/05/17/first-human-immunotherapy-treatment-trial-creutzfeldt
|
|
[23]
|
Liu, F., Lü, W. and Liu, L. (2024) New Implications for Prion Diseases Therapy and Prophylaxis. Frontiers in Molecular Neuroscience, 17, Article ID: 1324702. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Boston University School of Medicine (2024) Drug Compounds to Combat Neurodegenerative Diseases. ScienceDaily. https://www.sciencedaily.com/releases/2024/05/240515122734.htm
|